Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Eli Lilly and Co. won European approval today for its once-daily version of the impotence pill Cialis, Reuters reported.
The OK from the European Commission could help Lilly differentiate its erectile dysfunction therapy from competitor Viagra. Before, Cialis and Pfizer Inc.’s Viagra have been taken as needed.
But now, the new low-dose formulation of Cialis is taken continually, eliminating the need to plan sex within a limited time frame. Lilly plans to start launching the once-daily version in certain European countries in the second half of this year.
Cialis is one of Lilly’s fastest-growing drugs. Its worldwide sales rose 19 percent in Lilly’s first quarter, to $266 million.
Please enable JavaScript to view this content.